Synergistic antidiabetic effects of GC-MS profiled Prunus persica kernel extract and chromium picolinate in alloxan-induced diabetic rats.

Diabetes mellitus continues to be a significant worldwide health burden, necessitating safe and efficient treatment alternatives. In alloxan-induced diabetic rats, this study examined the combined antidiabetic effectiveness of chromium picolinate and Prunus persica kernel extract. Gas chromatography/mass spectrometry was used to phytochemically characterize a polyphenolic-rich extract (60% acetone). Alloxan monohydrate (140 mg/kg b.w.) was administered intraperitoneally to develop diabetes in rats. The animals were split into groups for normal control, diabetic control, chromium picolinate, Prunus kernel extract, three combination therapy groups, and conventional medication. The treatments were administered orally on a 21-day basis. Insulin levels in serum were also measured following dissection, and body weight and fasting blood glucose (FBG) were monitored prior to and after treatment. Pancreatic tissue was taken in order to determine the preservation and regeneration of B-cells through a histological analysis. Compared to individual therapy, the combined therapy had a significant benefit of reducing the level of FBG (p < .01), increasing serum insulin significantly, and rescuing the morphology of the pancreatic B-cells. These findings confirm the P. persica kernel extracts and chromium picolinate as supplementation therapies in diabetes management because they suggest that the two compounds act synergistically to enhance pancreatic protection and control glucose levels.